XM nie świadczy usług obywatelom Stanów Zjednoczonych.
S
S

Sanofi


Wiadomości

Column: Will Zantac ruling make Delaware a mass torts magnet?

Column: Will Zantac ruling make Delaware a mass torts magnet? The opinions expressed here are those of the author, a columnist for Reuters. By Alison Frankel June 3 (Reuters) - If you are mass torts lawyer, you should be paying attention to a trend that has emerged in litigation over the discontinued heartburn medication Zantac. On Friday, as my Reuters colleague Brendan Pierson reported , a Delaware Superior Court judge ruled that nearly 75,000 lawsuits alleging that Zantac causes cancer can mo
G
P
S

Sanofi Says Sarclisa Is First Anti-Cd38 To Improve Progression-Free Survival For Diagnosed Transplant-Ineligible Multiple Myeloma In Phase 3

BRIEF-Sanofi Says Sarclisa Is First Anti-Cd38 To Improve Progression-Free Survival For Diagnosed Transplant-Ineligible Multiple Myeloma In Phase 3 June 3 (Reuters) - Sanofi SA SASY.PA : REG-PRESS RELEASE: ASCO: SARCLISA IS FIRST ANTI-CD38 TO SIGNIFICANTLY IMPROVE PROGRESSION-FREE SURVIVAL IN COMBINATION WITH VRD FOR NEWLY DIAGNOSED TRANSPLANT-INELI
S

Investors prescribe harsh medicine for GSK’s boss

BREAKINGVIEWS-Investors prescribe harsh medicine for GSK’s boss The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Refiles to change ambiguous ‘them’ in fifth paragraph to ‘investors’. By Yawen Chen LONDON, June 3 (Reuters Breakingviews) - GSK GSK.L investors are having a panic attack. Jittery shareholders of the $93 billion British drugmaker on Monday wiped $9 billion off its value after a U.S.
A
G
S

Deutsche Post Group - Dhl Supply Chain Partners with Sanofi

BRIEF-Deutsche Post Group - Dhl Supply Chain Partners with Sanofi June 3 (Reuters) - DEUTSCHE POST AG DHLn.DE : DHL SUPPLY CHAIN EXPANDS PHARMA LOGISTICS OPERATIONS IN FRANCE DHL SUPPLY CHAIN HAS EXPANDED ITS SPECIALIZED LOGISTICS SERVICES FOR THE LIFE SCIENCES AND HEALTHCARE SECTOR IN FRANCE THROUGH A LONG-TERM STRATEGIC PARTNERSHIP WITH SANOFI DH
S

GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed

UPDATE 2-GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed Updates shares and adds more analysts in paragraphs 7-11 By Yadarisa Shabong and Maggie Fick June 3 (Reuters) - Shares of GSK GSK.L dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker.
G
P
S

Sanofi Pushes Ahead With 20 Bln Euros Consumer Healthcare Spin-Off - FT

BRIEF-Sanofi Pushes Ahead With 20 Bln Euros Consumer Healthcare Spin-Off - FT June 2 (Reuters) - SANOFI PUSHES AHEAD WITH €20BN CONSUMER HEALTHCARE SPIN-OFF - FT GOLDMAN SACHS, MORGAN STANLEY WILL WORK WITH BNP PARIBAS & BANK OF AMERICA ON SALE; POTENTIAL FLOAT EXPECTED TO TAKE PLACE AS SOON AS END OF YEAR - FT Source text: https://on.ft.com/4bXj
S

Delaware judge lets more than 70,000 Zantac lawsuits go forward

UPDATE 2-Delaware judge lets more than 70,000 Zantac lawsuits go forward Adds detail from opinion in paragraphs 3-4 By Brendan Pierson June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer. The ruling on Friday by Judge Vivian Medinilla of the Delaware Superior Court in Wilmington is a setback for former Zantac makers GSK GSK.L , Pfizer PFE.N
G
P
S

Delaware judge lets more than 70,000 Zantac lawsuits go forward

Delaware judge lets more than 70,000 Zantac lawsuits go forward June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer. The ruling on Friday by Judge Vivian Medinilla of the Delaware Superior Court in Wilmington is a setback for former Zantac makers GSK GSK.L , Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim, which had argued that the e
G
P
S

EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review

UPDATE 1-EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review Adds details from EMA disclosure and background throughout May 31 (Reuters) - Sanofi SASY.PA and partner Regeneron Pharmaceuticals REGN.O have secured the European regulator's backing for use of Dupixent in patients with a chronic lung disease even as the U.S. Food and Drug Administration (FDA) extended its review.
R
S

EMA Says Valneva's Chikungunya Vaccine Receives Positive CHMP Opinion

BRIEF-EMA Says Valneva's Chikungunya Vaccine Receives Positive CHMP Opinion May 31 (Reuters) - EMA: EMA SAYS IXCHIQ (CHIKUNGUNYA VACCINE (LIVE)) RECEIVED POSITIVE CHMP OPINION EMA:CHMP GAVE RECOMMENDATION FOR CONDITIONAL MARKETING AUTHORISATION FOR DURVEQTIX(FIDANACOGENE ELAPARVOVEC), GENE THERAPY TREATMENT FOR HAEMOPHILIA EMA SAYS CHMP HAS RESTART
P
S

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung'

FDA extends deadline, requests more data on Sanofi's Dupixent for treating 'smoker's lung' May 31 (Reuters) - French drugmaker Sanofi SASY.PA and its partner Regeneron REGN.O said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in certain patients 'smoker's lung', or COPD.
R
S

Sanofi: Dupixent Recommended For EU Approval By CHMP For Patients With COPD

BRIEF-Sanofi: Dupixent Recommended For EU Approval By CHMP For Patients With COPD May 31 (Reuters) - Sanofi SA SASY.PA : DUPIXENT RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT PATIENTS WITH COPD RECOMMENDATION FOR ADULTS WITH UNCONTROLLED COPD WITH RAISED BLOOD EOSINOPHILS BASED ON DATA FROM TWO LANDMARK PHASE 3 TRIALS EUROPEAN COMMISSION IS EXP
S

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch May 31 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. RENAULT RENA.PA The French automaker and Chinese peer Geely on Friday announced the creation of a 50-50 joint venture for hybrid and combustion powertrain components and systems.
R
R
S
T
V
F
N
U

Regeneron Pharmaceuticals Says European Commission Is Expected To Announce Final Decision On Dupixent Application In Coming Months.

BRIEF-Regeneron Pharmaceuticals Says European Commission Is Expected To Announce Final Decision On Dupixent Application In Coming Months. May 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : DUPIXENT® (DUPILUMAB) RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT PATIENTS WITH COPD EUROPEAN COMMISSION IS EXPECTED TO ANNOUNCE A FINAL DECISION ON DUPIXENT APPLICATION IN COMING MONTHS.
R
S

Sanofi: FDA Extends Review Of Dupixent For Treatment Of COPD Patients

BRIEF-Sanofi: FDA Extends Review Of Dupixent For Treatment Of COPD Patients May 31 (Reuters) - Sanofi SA SASY.PA : UPDATE ON FDA PRIORITY REVIEW OF DUPIXENT FOR TREATMENT OF COPD PATIENTS WITH TYPE 2 INFLAMMATION US FOOD AND DRUG ADMINISTRATION (FDA) HAS EXTENDED BY THREE MONTHS TARGET ACTION DATE OF ITS PRIORITY REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR DUPIXENT (DUPILUMAB) REVISED TARGET ACTION DATE IS SEPTEMBER 27, 2024 FDA DID NOT RAISE ANY CONCERNS REGARDING APPROVABIL
R
S

Regeneron Issues Update On FDA Priority Review Of Dupixent

BRIEF-Regeneron Issues Update On FDA Priority Review Of Dupixent May 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : UPDATE ON FDA PRIORITY REVIEW OF DUPIXENT® (DUPILUMAB) FOR THE TREATMENT OF COPD PATIENTS WITH TYPE 2 INFLAMMATION FDA DID NOT RAISE ANY CONCERNS REGARDING APPROVABILITY OF DUPIXENT FOR THIS INDICATION. REVISED TARGET ACTION D
R
S

What to know about bird flu in dairy cows and the risk to humans

EXPLAINER-What to know about bird flu in dairy cows and the risk to humans Adds details on third human case in paragraph 1, 2; updates throughout By Julie Steenhuysen CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak.
G
S

Sanofi Completes Acquisition Of Inhibrx, Inc.

BRIEF-Sanofi Completes Acquisition Of Inhibrx, Inc. May 30 (Reuters) - Sanofi SA SASY.PA : SANOFI COMPLETES ACQUISITION OF INHIBRX, INC. ACQUISITION ADDS SAR447537 (FORMERLY INBRX-101) TO SANOFI'S RARE DISEASE PIPELINE UPON CLOSING OF ACQUISITION, FORMER SHAREHOLDERS OF INHIBRX BECAME ENTITLED TO RECEIVE $30.00 PER SHARE IN CASH CLOSING OF ACQUISIT
S

France against Servier selling generics unit Biogaran, PM says

UPDATE 1-France against Servier selling generics unit Biogaran, PM says Adds quotes from French PM, context and background in paragraphs 3-9 PARIS, May 29 (Reuters) - The French government has told drugmaker Servier it is against any sale of its generics subsidiary Biogaran, which has a market share of almost a third in the country, Prime Minister Gabriel Attal said on Wednesday.
A
S

EU approves $1.5 bln state funded joint hydrogen scheme

UPDATE 1-EU approves $1.5 bln state funded joint hydrogen scheme Adds European Commission Vice President Margrethe Vestager comment from press conference, details By Foo Yun Chee BRUSSELS, May 28 (Reuters) - European Union competition regulators approved on Tuesday a 1.4-billion-euro ($1.52 billion) hydrogen schemed to be funded by seven EU countries which they expect to unlock an additional 3.3 billion euros in private investments.
A
B
S
A



Warunki

Popularne aktywa

Wyłączenie odpowiedzialności: Każdy z podmiotów należących do XM Group świadczy usługę polegającą wyłącznie na realizacji zleceń i dostępie do naszej internetowej platformy transakcyjnej, umożliwiając danej osobie przeglądanie i/lub korzystanie z treści dostępnych na stronie lub za jej pośrednictwem, co nie ma na celu zmiany lub rozszerzenia tego zakresu, ani nie zmienia i nie rozszerza go. Taki dostęp i korzystanie z niego podlegają w każdej chwili: (i) Warunkom umowy, (ii) Ostrzeżeniom o ryzyku i (iii) Pełnemu wyłączeniu odpowiedzialności. Treści te są zatem podawane wyłącznie jako informacje ogólne. W szczególności należy pamiętać, że treści zawarte na naszej internetowej platformie transakcyjnej nie stanowią oferty ani zaproszenia do zawarcia jakichkolwiek transakcji na rynkach finansowych. Transakcje na każdym rynku finansowym wiążą się ze znacznym poziomem ryzyka dla twojego kapitału.

Wszystkie materiały publikowane na naszej internetowej platformie transakcyjnej są przeznaczone wyłącznie do celów edukacyjnych/informacyjnych i nie zawierają – i nie powinny być uważane za zawierające – porad ani rekomendacji dotyczących finansów, inwestycji, podatków lub transakcji, zapisu naszych cen transakcyjnych, ani też oferty lub zaproszenia do transakcji na jakichkolwiek instrumentach lub niezamówionych promocji finansowych.

Wszelkie treści pochodzące od podmiotów trzecich, jak i treści przygotowane przez XM, takie jak opinie, wiadomości, badania, analizy, ceny i inne informacje lub linki do stron podmiotów trzecich zawarte na tej stronie internetowej są udostępniane na zasadzie „tak, jak jest” jako ogólny komentarz rynkowy i nie stanowią porady inwestycyjnej. W zakresie, w jakim jakakolwiek treść jest interpretowana jako badania inwestycyjne, należy zauważyć i zaakceptować, że treść ta nie była przeznaczona i nie została przygotowana zgodnie z wymogami prawnymi mającymi na celu promowanie niezależności badań inwestycyjnych i jako taka byłaby uważana za komunikat marketingowy w świetle odpowiednich przepisów prawnych i regulacji. Upewnij się, że przeczytałeś(-aś) i rozumiesz nasze dokumenty Powiadomienie o zależnych badaniach inwestycyjnych oraz Ostrzeżenie o ryzyku, dotyczące powyższych informacji, do których można uzyskać dostęp tutaj.

Ostrzeżenie o ryzyku: Twój kapitał jest zagrożony. Produkty z zastosowaniem dźwigni mogą nie być odpowiednie dla każdego inwestora. Zapoznaj się z Ujawnieniem ryzyka.